Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (greater than or equal to 16 to 80 Years Old) With Partial Onset Seizures

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (greater than or equal to 16 to 80 Years Old) With Partial Onset Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Partial epilepsies; Seizures
  • Focus Registrational; Therapeutic Use
  • Acronyms BRITE
  • Sponsors UCB; UCB Biosciences; UCB Pharma Inc

Most Recent Events

  • 01 Jan 2023 Results of post hoc analysis evaluating long-term retention, reasons for discontinuation, efficacy, tolerability, and health-related quality of life (HRQOL) during adjunctive brivaracetam (BRV) treatment in adults with focal seizures by number of lifetime antiseizure medications published in the Epilepsy and Behavior
  • 17 May 2022 Results of pooled post hoc (N01252/NCT00490035, N01253/NCT00464269, and N01358/NCT01261325 studies) analysis published in the Epilepsia
  • 26 Apr 2022 Results of post hoc analysis of 3 phase III trials (N01252 [NCT00490035], N01253 [NCT00464269], N01358 [NCT01261325]) assessing the time-course of treatment-emergent adverse events (TEAEs) potentially associated with behavioral disorders (BAEs) in adults with focal seizures during adjunctive brivaracetam (BRV) treatment presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top